Newsmakers: Cyclacel Pharmaceuticals, Eli Lilly & Co, Aegerion Pharmaceuticals, Delcath Systems Are Notable Movers Print
Monday, 15 October 2012 14:01
Stocks advanced on Monday as optimism about stronger-than-expected Citigroup earnings and retail sales, along with a rebound in energy shares, put investors in the mood to buy.

September retail sales rose 1.1 percent, above the 0.8 percent growth that had been anticipated, but a survey showed that an index of manufacturing activity in New York state shrank for the third month in a row in October.

Following are the notable movers at mid day on Monday:

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)
is the biggest gainer and soared 31% to $7.15 after hitting a 52-week high of $7.93. The company announced Phase 2 results of oral sapacitabine capsules Monday morning, which showed that expected survival of elderly patients with MDS nearly doubled.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)
stock gained 7.89% to $17.22. U.S. Food and Drug Administration medical reviewers said a proposed Aegerion drug that would treat a rare genetic disorder that causes very high cholesterol is effective at reducing cholesterol but there's a potential for it to cause liver damage.

Eli Lilly & Co. (NYSE:LLY)
shares climbed 4.10% to $52.52 in the early hour after the company announced the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab. The REGARD trial compared ramucirumab and supportive care to placebo and supportive care as a second-line treatment in patients with metastatic gastric and
gastroesophageal junction cancers.

Horizon Pharma Inc. (NASDAQ:HZNP)
stock increased 0.92% to $3.30 after the company announced that SkyePharmahas received a Notice of Allowance from the United States Patent andTrademark Office for U.S. Patent Application 2012/0177734 entitled"Delayed Release Tablet with Defined Core Geometry" that covers the U.S. approved product RAYOS(R).

Depomed Inc. (NASDAQ:DEPO)
shares climbed 3.33% to $6.25 in the early hour after the company announced that New Drug Application (NDA) for Serada has been accepted for filing by the U.S. Food and Drug Administration (FDA). Depomed submitted the Serada NDA to FDA on July 31, 2012. Depomed is seeking approval to market and

Error. Page cannot be displayed. Please contact your service provider for more details. (1)

sell Serada in the United States for the treatment of menopausal hot flashes. Serada is an investigational product and
is not approved to treat any disease or condition.

Delcath Systems, Inc. (NASDAQ:DCTH)
shares dropped 16.82% to $1.74 after the company announced that the New Drug Application for its CHEMOSAT hepatic chemosaturation system has been accepted by the FDA with a standard review designation. DCTH investors had hoped for a priority review from the FDA, which would have expedited the review process from 10 months for a standard designation, to 6 months, allowing CHEMOSAT to enter the domestic market as early as the first quarter of next year if approved.



BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
  BMR:1